Discovery of new pharmaceuticals for the treatment of cancer within the field of epigenetics.

Invested: 2010

Sold to Gilead in 2015

Lundbeckfonden Emerge


Dermtreat secures GMP manufacturing
4. September 2017
Dermtreat Raises USD 17.7 mill. From Sofinnova Ventures, Novo A/S and Lundbeckfonden
8. May 2017
Rare Neuromuscular Disease Company NMD Pharma Raises USD 3 Million in Seed Financing Round
13. June 2016